Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
About this item
Full title
Author / Creator
Socinski, Mark A , Jotte, Robert M , Cappuzzo, Federico , Orlandi, Francisco , Stroyakovskiy, Daniil , Nogami, Naoyuki , Rodríguez-Abreu, Delvys , Moro-Sibilot, Denis , Thomas, Christian A , Barlesi, Fabrice , Finley, Gene , Kelsch, Claudia , Lee, Anthony , Coleman, Shelley , Deng, Yu , Shen, Yijing , Kowanetz, Marcin , Lopez-Chavez, Ariel , Sandler, Alan , Reck, Martin and IMpower150 Study Group
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not previously received chemotherapy for metastatic NSCLC, regardless of PD-L1 expression and
EGFR
or
ALK
genomic alteration status.
Alternative Titles
Full title
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Authors, Artists and Contributors
Author / Creator
Jotte, Robert M
Cappuzzo, Federico
Orlandi, Francisco
Stroyakovskiy, Daniil
Nogami, Naoyuki
Rodríguez-Abreu, Delvys
Moro-Sibilot, Denis
Thomas, Christian A
Barlesi, Fabrice
Finley, Gene
Kelsch, Claudia
Lee, Anthony
Coleman, Shelley
Deng, Yu
Shen, Yijing
Kowanetz, Marcin
Lopez-Chavez, Ariel
Sandler, Alan
Reck, Martin
IMpower150 Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2070387156
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2070387156
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1716948
